About

Dr. Kristine H Jang is an Associate Professor in Medicine at Stony Brook University. She specializes in Heart Failure and Transplantation Cardiology, with expertise in Cardiology and Cardio-Oncology. Her educational background includes a fellowship at Memorial Sloan-Kettering Cancer Center in 2020, a residency at Northwell Health at Northshore University Hospital in Internal Medicine and Advanced Heart Failure in 2020, a fellowship at Cooper University Hospital in Cardiovascular Medicine in 2019, and a residency at Stony Brook University Medical Center in General Medicine completed in 2016. She earned her medical degree from NYIT College of Osteopathic Medicine in 2013. Dr. Jang is board certified in Advanced Heart Failure and Transplant Cardiology (2024), Cardiovascular Disease (2022), and Internal Medicine (2021). She is fluent in Korean and English and actively accepts new patients for her specialty care services.

Research topics

• Medicine
• Political Science
• Internal medicine
• Economic geography
• Geography
• Virology
• Medical emergency
• Nursing
• Archaeology

Selected publications

• Association of early dexrazoxane with reduced cardiotoxicity risk in sarcoma patients treated with anthracycline chemotherapy

  The Oncologist · 2025-11-05 · 1 citations

  articleOpen access1st authorCorresponding

  BACKGROUND: Cardiotoxicity is a concern for patients with sarcoma receiving anthracyclines. Dexrazoxane reduces this risk; however, the timing of administration varies in practice. This study evaluated the association between dexrazoxane timing and anthracycline cardiotoxicity risk. PATIENTS AND METHODS: This retrospective, single-center cohort study included adults with sarcoma treated with anthracyclines from 2010 to 2020 with a baseline and ≥1 follow-up echocardiogram. "Early" dexrazoxane was defined as starting with the first anthracycline dose; "later" as starting with the second or subsequent doses. The primary endpoint was time to cardiotoxicity (decline in left ventricular ejection fraction [LVEF] ≥10%-<50% from baseline). Associations were evaluated using multivariable Cox proportional hazards models. RESULTS: Among 672 patients, the median doxorubicin-equivalent dose was 300 mg/m2 (interquartile range [IQR]: 200-444 mg/m2); dexrazoxane was administered early in 130 patients (19.3%) and later in 275 (40.9%). Over a median follow-up of 8.6 months (IQR: 3.9-23.1 months), 48 (7.1%) developed cardiotoxicity. Among patients who received a cumulative anthracycline dose >300 mg/m2, those receiving early dexrazoxane had an 85% reduction in cardiotoxicity risk (hazard ratio, 0.15; 95% CI, 0.02-0.99) compared to those who did not receive dexrazoxane, adjusting for age, diabetes, and baseline LVEF. Early dexrazoxane was not significantly associated with cardiotoxicity risk among patients who received a cumulative anthracycline dose ≤300 mg/m2. CONCLUSIONS: Early dexrazoxane is significantly associated with lower cardiotoxicity risk in adults with sarcoma receiving anthracycline doses >300 mg/m2. These findings support the potential benefit of early dexrazoxane use in patients at elevated risk for anthracycline-induced cardiotoxicity; however, further validation is warranted.

  PublisherOA PDFDOI

• Improvement in global longitudinal strain following plasma cell-directed therapy is associated with long-term survival among patients with AL amyloidosis

  European Heart Journal Open · 2025-08-15 · 3 citations

  articleOpen access1st authorCorresponding

  Aims: Cardiac impairment in AL amyloidosis is the major determinant of survival. Treatment goals include reducing circulating light chains to improve organ function. Global longitudinal strain (GLS) is an independent predictor of survival and useful for assessing cardiac function before and after therapy. This study aimed to describe GLS change from baseline to one year post-treatment, identify factors associated with GLS improvement (GLS+), and evaluate its prognostic significance. Methods and results: Ninety-seven patients with AL amyloidosis and cardiac stage II/III disease who underwent echocardiogram and haematologic evaluation at baseline and one year were included. GLS+ was defined as a 2.0%-point increase. A cardiac or B-type natriuretic peptide (BNP+) response was defined as a 30% reduction from baseline. Overall survival was measured from baseline echocardiogram to death. Of 97 patients, 62% had Stage II, 29% Stage IIIa, and 9% Stage IIIb disease. Baseline median left ventricular ejection fraction, GLS, and septal thickness were 65%, -14.9%, and 1.3 cm, respectively. GLS+ was observed in 36% of patients and BNP+ in 51%. Median overall survival was 113.4 months. The hazard ratio for survival was 0.42 in the GLS+ group and 0.46 in the BNP+ group, after adjusting for haematologic response. Conclusion: GLS improvement post-treatment confers a significant survival benefit. This study supports GLS as an important marker for risk stratification and cardiac response.

  PublisherOA PDFDOI

• EVALUATION OF EARLY DEXRAZOXANE USE AND CARDIOTOXICITY RISK IN PATIENTS WITH SOFTTISSUE SARCOMA TREATED WITH ANTHRACYCLINES

  Journal of the American College of Cardiology · 2024-04-01 · 1 citations

  article1st authorCorresponding
  PublisherDOI

• Abstract 12171: Cardiovascular Events in Chimeric Antigen Receptor T-Cell Therapy Recipients With Pre-Existing Cardiac Dysfunction

  Circulation · 2022-11-08

  article

  Introduction: Cytokine release syndrome (CRS) and associated cardiovascular (CV) events are common following infusion of chimeric antigen receptor T cell therapy (CAR-T). There are no data characterizing whether CAR-T recipients with a pre-existing cardiac dysfunction (LVEF &lt;53%) are at increased risk for CV events following CAR-T. Hypothesis: We hypothesized that cardiac dysfunction would be associated with a higher rate of CV events following CAR-T infusion. CV events were defined as a composite of cardiogenic shock, clinical heart failure, myocardial infarction, or arrhythmia. Methods: Patients in a multi-center registry of adult CAR-T recipients with a known baseline LVEF were included (n=241). Covariates included standard baseline CV and cancer parameters. Results: In total, 22 (9%) CAR-T patients had a pre-existing cardiac dysfunction. Those with and without [219 (91%)] baseline cardiac dysfunction were similar in age, gender, pre-existing CV risk factors, and ECOG performance status. LVEF among patients with cardiac dysfunction ranged from 25%-52%. There was no difference in prior anthracycline use, cancer type or burden, but cardiac dysfunction patients had higher rates of prior radiation (36% vs 16%, p=0.02). Cardiac dysfunction patients received less investigational CAR-T (9% vs 31%, p=0.03), more tisagenlecleucel (36% vs 18%, p=0.04), and had similar rates of axicabtagene ciloleucel and lisocabtagene maraleucel. There was no difference in mean CRS grade, rate of ≥2 grade CRS, or in tocilizumab or steroids use between those with and without cardiac dysfunction. During a median follow-up of 294 (IQR 123-661) days, 60 (25%) patients experienced CV events with more events in patients with cardiac dysfunction (63% vs 21%, p&lt;0.001). In a Cox model adjusted for covariates identified in univariate analyses, baseline cardiac dysfunction was independently associated with an increased CV events risk (adjusted HR: 4.9, 95% CI 2.54–9.61, p&lt;0.001) Conclusions: CAR-T recipients with pre-existing cardiac dysfunction experience more CV events despite similar rates of CRS.

  PublisherDOI

• Assessment of New York City Urgent Care Centers’ Emergency Preparedness and Infection Prevention and Control Practices, 2016–2017

  Disaster Medicine and Public Health Preparedness · 2021

  • Political Science
  • Medical emergency
  • Medicine

  BACKGROUND: Urgent care centers (UCCs) have become frontline healthcare facilities for individuals with acute infectious diseases. Additionally, UCCs could potentially support the healthcare system response during a public health emergency. Investigators sought to assess NYC UCCs' implementation of nationally-recommended IPC and EP practices. METHODS: Investigators identified 199 eligible UCCs based on criteria defined by the Urgent Care Association of America. Multiple facilities under the same ownership were considered a network. As part of a cross-sectional analysis, an electronic survey was sent to UCC representatives assessing their respective facilities' IPC and EP practices. Representatives of urgent care networks responded on behalf of all UCCs within the network if all sites within the network used the same policies and procedures. RESULTS: Of the respondents, 18 representing 144 UCCs completed the survey. Of these, 8 of them (44.4% of the respondents) represented more than 1 facility that utilized standardized practices (range = 2-60 facilities). Overall, 81.3% have written IPC policies, 75.0% have EP policies, 80.6% require staff to train on IPC, and 75.7% train staff on EP. CONCLUSION: Most UCCs reported implementation of IPC and EP practices; however, the comprehensiveness of these activities varied across UCCs. Public health can better prepare the healthcare system by engaging UCCs in planning and executing of IPC and EP-related initiatives.

  PublisherOA PDFDOI

• Cardio-Oncology in the COVID-19 Era

  Springer eBooks · 2021 · 1 citations

  • Virology
  • Medicine
  • Geography
  PublisherDOI

• COVID‐19 in recent heart transplant recipients: Clinicopathologic features and early outcomes

  Transplant Infectious Disease · 2020 · 47 citations

  • Medicine
  • Internal medicine

  BACKGROUND: The impact of COVID-19 on heart transplant (HTx) recipients remains unclear, particularly in the early post-transplant period. METHODS: We share novel insights from our experience in five HTx patients with COVID-19 (three within 2 months post-transplant) from our institution at the epicenter of the pandemic. RESULTS: All five exhibited moderate (requiring hospitalization, n = 3) or severe (requiring ICU and/or mechanical ventilation, n = 2) illness. Both cases with severe illness were transplanted approximately 6 weeks before presentation and acquired COVID-19 through community spread. All five patients were on immunosuppressive therapy with mycophenolate mofetil (MMF) and tacrolimus, and three that were transplanted within the prior 2 months were additionally on prednisone. The two cases with severe illness had profound lymphopenia with markedly elevated C-reactive protein, procalcitonin, and ferritin. All had bilateral ground-glass opacities on chest imaging. MMF was discontinued in all five, and both severe cases received convalescent plasma. All three recent transplants underwent routine endomyocardial biopsies, revealing mild (n = 1) or no acute cellular rejection (n = 2), and no visible viral particles on electron microscopy. Within 30 days of admission, the two cases with severe illness remain hospitalized but have clinically improved, while the other three have been discharged. CONCLUSIONS: COVID-19 appears to negatively impact outcomes early after heart transplantation.

  PublisherOA PDFDOI

• COVID-19 leading to acute encephalopathy in a patient with heart transplant

  The Journal of Heart and Lung Transplantation · 2020-06-06 · 13 citations

  letterOpen access1st author
  PublisherOA PDFDOI

• Combined aquaretic and diuretic therapy in acute heart failure

  International Journal of Nephrology and Renovascular Disease · 2017-06-01 · 10 citations

  articleOpen access

  Introduction: Acute heart failure (AHF) is a leading cause of hospitalization and readmission in the US. The present study evaluated maximum diuresis while minimizing electrolyte imbalances, hemodynamic instability, and kidney dysfunction, to achieve a euvolemic state safely in a shorter period of time. Methods and results: A protocol of combined therapy with furosemide, metolazone, and spironolactone, with or without tolvaptan and acetazolamide, was used in 17 hospitalized patients with AHF. The mean number of days on combination diuretic protocol was 3.8 days. The mean daily fluid balance was 3.0±2.1 L negative. The mean daily urine output (UOP) was 4.1±2.0 L (range 1.8–10.5 L). There were minimal fluctuations in serum electrolyte levels and serum creatinine over the duration of diuretic therapy. There was no statistically significant change in patients’ creatinine from immediately prior to therapy to the last day of therapy, with a mean increase in creatinine of 0.14 mg/dL (95% CI −0.03, +0.30, p =0.10). Conclusion: Our strategy of treating AHF by achieving high UOP, while maintaining stable electrolytes and creatinine in a short period to euvolemic state, is safe. Keywords: diuretics, aquaretic, acute heart failure, volume overload

  PublisherOA PDFDOI

• Ionic liquid and plasma effects on SiO2 supported Pd for selective hydrogenation of acetylene

  Catalysis Today · 2013-03-29 · 25 citations

  article
  PublisherDOI

Frequent coauthors

• Jasmine Jacobs-Wingo

  Office of Readiness and Response

  6 shared

• John P. Leonard

  Weill Cornell Medicine

  2 shared

• Irina Sobol

  2 shared

• Rebecca Thomas

  2 shared

• Vanesa Bijol

  2 shared

• Fran Wallach

  Hofstra University

  2 shared

• Mary Foote

  New York City Department of Health and Mental Hygiene

  2 shared

• Kathryn Malhame

  North Shore University Hospital

  2 shared